Drug Profile
Interferon alpha controlled-release - Hepasome Pharmaceuticals
Alternative Names: Controlled-release IFN-alpha - Hepasome Pharmaceuticals; HDV-IFN; HDV-InterferonLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Hepasome Pharmaceuticals
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 07 Aug 2015 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in India (SC)
- 07 Aug 2015 No recent reports on development identified - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in India (PO)
- 31 May 2008 Phase-II clinical trials in Hepatitis C in India (PO)